Keiichiro Mori1,2, Hadi Mostafaei1,3, Mohammad Abufaraj1,4, Lin Yang5,6, Shin Egawa2, Shahrokh F Shariat1,4,7,8,9,10,11,12. 1. Department of Urology, Medical University of Vienna, Vienna, Austria. 2. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. 3. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. 5. Department of Cancer Epidemiology and Prevention Research, Alberta Health Services. 6. Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. 7. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. 8. Department of Urology, Weill Cornell Medical College, New York, New York. 9. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. 10. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. 11. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. 12. European Association of Urology Research Foundation, Arnhem, Netherlands.
Abstract
PURPOSE OF REVIEW: This review summarizes the current knowledge regarding the relationship between smoking and bladder cancer (BCa), especially with respect to treatment outcomes for muscle and nonmuscle-invasive BCa (MIBC/NMIBC). RECENT FINDINGS: PubMed/Medline databases were searched for recent reports investigating the association of smoking with BCa. Smoking is associated with an increased risk of recurrence in patients with NMIBC and may impair Bacillus Calmette-Guerin treatment efficacy. Moreover, smoking is associated with poor responses to neoadjuvant chemotherapy, poor survival outcomes and high complication rates in patients undergoing radical cystectomy. Smoking cessation mitigates these negative effects, especially. However, the amount of patient counselling provided regarding this important matter and patient knowledge regarding smoking and BCa risk are inadequate. Currently, the impact of secondhand smoke on BCa risk remains uncertain. SUMMARY: Tobacco smoking is responsible for approximately half of BCa cases, and is associated with poor oncological outcomes for both NMIBC and MIBC. Despite smoking being a well known risk factor, counselling and knowledge in this area are insufficient. Appropriate smoking cessation interventions and patient information are required to improve patient health and optimize BCa survival.
PURPOSE OF REVIEW: This review summarizes the current knowledge regarding the relationship between smoking and bladder cancer (BCa), especially with respect to treatment outcomes for muscle and nonmuscle-invasive BCa (MIBC/NMIBC). RECENT FINDINGS: PubMed/Medline databases were searched for recent reports investigating the association of smoking with BCa. Smoking is associated with an increased risk of recurrence in patients with NMIBC and may impair Bacillus Calmette-Guerin treatment efficacy. Moreover, smoking is associated with poor responses to neoadjuvant chemotherapy, poor survival outcomes and high complication rates in patients undergoing radical cystectomy. Smoking cessation mitigates these negative effects, especially. However, the amount of patient counselling provided regarding this important matter and patient knowledge regarding smoking and BCa risk are inadequate. Currently, the impact of secondhand smoke on BCa risk remains uncertain. SUMMARY:Tobacco smoking is responsible for approximately half of BCa cases, and is associated with poor oncological outcomes for both NMIBC and MIBC. Despite smoking being a well known risk factor, counselling and knowledge in this area are insufficient. Appropriate smoking cessation interventions and patient information are required to improve patient health and optimize BCa survival.
Authors: Keiichiro Mori; Takafumi Yanagisawa; Satoshi Katayama; Ekaterina Laukhtina; Benjamin Pradere; Hadi Mostafaei; Fahad Quhal; Pawel Rajwa; Marco Moschini; Francesco Soria; David D'andrea; Mohammad Abufaraj; Simone Albisinni; Wojciech Krajewski; Wataru Fukuokaya; Jun Miki; Takahiro Kimura; Shin Egawa; Jeremy Yc Teoh; Shahrokh F Shariat Journal: World J Urol Date: 2022-08-13 Impact factor: 3.661
Authors: Klaus Golka; Ralf Böthig; Wobbeke Weistenhöfer; Olaf P Jungmann; Steffi Bergmann; Michael Zellner; Wolfgang Schöps Journal: Urologie Date: 2022-09-26
Authors: Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk Journal: Nat Rev Urol Date: 2022-03-31 Impact factor: 16.430
Authors: Frederik König; Benjamin Pradere; Nico C Grossmann; Fahad Quhal; Pawel Rajwa; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Takafumi Yanagisawa; Hadi Mostafai; Reza Sari Motlagh; Abdulmajeed Aydh; Roland Dahlem; Shahrokh F Shariat; Michael Rink Journal: Transl Cancer Res Date: 2022-04 Impact factor: 1.241
Authors: Alana M Rojewski; Lisa M Fucito; Nathaniel L Baker; Amanda M Palmer; Madeline G Foster; Graham W Warren; Steven L Bernstein; Benjamin A Toll Journal: BMJ Open Date: 2021-06-29 Impact factor: 2.692